Pro-Dex, Inc. PDEX R2K

Q: What is the current share price of Pro-Dex, Inc. (PDEX)?

As of 2026-07-14 21:23 PDT, Pro-Dex, Inc. (PDEX) trades at $58.26 on NasdaqCM. Its 52-week range is $23.91 to $67.50.

Q: What is the market capitalisation of PDEX?

Pro-Dex, Inc. (PDEX) has a market capitalisation of $186.01M on NasdaqCM.

Q: What is the P/E ratio of PDEX?

PDEX trades at a trailing price-to-earnings (P/E) ratio of 16.05. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.40.

Q: What is the return on equity (ROE) of PDEX?

PDEX has a return on equity (ROE) of 29.83%. Its return on capital employed (ROCE) is 22.96%.

Q: Is PDEX a good stock to buy?

This page provides a data-driven analysis of Pro-Dex, Inc. (PDEX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Instruments & Supplies · United States

https://www.pro-dex.com

Company Profile ↓

$58.26

+26.02% 1Y

Mkt Cap$186.01M

P/E16.05

P/B4.40

52W High$67.50

52W Low$23.91

Book Value$14.14

EPS (TTM)$3.63

Company Overview

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 29.8%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 23.0%.

Reasonable Valuation

Trades at a P/E of 16.1, below the sector median of 25.4.

Healthy Margins

Maintains a net profit margin of 16.1%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Jun 2025 Revenue of $66.59M (+23.7% YoY); net profit $8.98M.
Trailing 12 Months Year-on-year growth — revenue +14.6%, earnings +22.4%.
5-Year Trend Long-term compounding — revenue CAGR 7.5%, profit CAGR 9.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	7.54%
1 Year:	14.60%

Compounded Profit Growth

5 Years:	9.14%
1 Year:	22.40%

Stock Price Performance

1 Year:	+26.02%
6 Months:	+39.58%
3 Months:	+11.18%
1 Month:	-7.41%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 79% of range

$23.91 $67.50

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)42.89 · Neutral

Price Performance

1M-7.41%

3M+11.18%

6M+39.58%

1Y+26.02%

Valuation vs Sector

P/E of 16.05 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 29.8%.
Healthy ROCE of 23.0%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

16.05

Industry PE

25.41

Forward P/E

28.28

PEG Ratio

Book Value

$14.14

Price to Book

4.40

P/S

2.66

EV/EBITDA

17.16

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

7.54%

Profit 5Y

9.14%

Revenue (YoY)

14.60%

Earnings (YoY)

22.40%

Profitability & Returns

ROCE

22.96%

ROE

29.83%

ROA

9.70%

Profit Margin

16.08%

Op Margin

15.51%

Gross Margin

27.78%

EPS (Latest Qtr)

$1.20

EPS (TTM)

$3.63

Balance Sheet & Liquidity

Debt/Equity

0.45

Quick Ratio

2.10

Current Ratio

3.67

Debt

$20.17M

Total Assets

$74.98M

Current Assets

Working Capital

Ownership

Promoter Holding

36.46%

Chg in Prom Hold

-0.03%

FII / Inst Holding

32.45%

Chg in FII Hold

0.15%

Financial Snapshot

Enterprise Value

$186.01M

Total Revenue (TTM)

$74.64M

EBITDA

$12.11M

Free Cash Flow

$5.40M

Operating Cash Flow

$7.34M

Shares Outstanding

3.19M

Gross Margin

27.78%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PDEX Pro-Dex, Inc. R2K	58.26	16.05	$186.01M	0.00%	22.96%	29.83%	7.54%	9.14%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2013	Mar 2014	Sep 2014	Dec 2014	Mar 2015	Sep 2015	Dec 2015	Mar 2016	Sep 2016	Dec 2016	Mar 2017	Sep 2017	Dec 2017	Mar 2018	Sep 2018	Dec 2018	Mar 2019	Sep 2019	Dec 2019	Mar 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Sep 2023	Dec 2023	Mar 2024	Sep 2024	Dec 2024	Mar 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	6.62M	5.16M	5.56M	5.49M	6.92M	6.40M	6.85M	7.24M	7.96M	8.51M	8.59M	8.27M	11.74M	-	9.99M	10.17M	9.27M	-	11.09M	11.28M	13.08M	11.94M	12.59M	14.29M	14.89M	16.79M	17.41M	18.53M	18.66M	19.95M
Gross Profit	549.00K	540.00K	828.00K	696.00K	1.04M	1.06M	1.43M	1.31M	1.42M	1.31M	2.46M	1.86M	1.72M	1.98M	2.73M	2.25M	2.26M	2.78M	2.86M	3.21M	3.48M	2.60M	4.38M	-	3.43M	3.40M	2.86M	-	2.96M	2.62M	3.81M	3.66M	2.80M	4.00M	5.15M	5.07M	5.80M	5.37M	5.74M	6.13M
Operating Income	-376.00K	-438.00K	-189.00K	-393.00K	-390.00K	-119.00K	486.00K	176.00K	294.00K	269.00K	1.35M	874.00K	350.00K	632.00K	1.73M	1.19M	897.00K	1.49M	1.67M	1.70M	1.55M	521.00K	1.86M	-	1.32M	1.60M	1.02M	-	950.00K	1.14M	2.06M	1.83M	777.00K	2.21M	3.01M	2.69M	3.64M	3.11M	3.26M	3.09M
Net Income	-338.00K	-385.00K	-170.00K	-192.00K	-76.00K	-125.00K	391.00K	368.00K	286.00K	3.19M	888.00K	628.00K	345.00K	480.00K	1.35M	1.18M	732.00K	1.10M	1.25M	1.21M	1.11M	1.79M	2.16M	1.11M	1.08M	1.08M	574.00K	1.84M	1.20M	2.75M	1.62M	-615.00K	500.00K	655.00K	2.47M	2.04M	3.27M	4.68M	2.19M	3.94M
Diluted EPS	-0.10	-	-0.04	-0.05	-0.02	-0.03	0.09	0.09	0.07	0.78	0.22	0.15	0.08	0.11	0.31	0.28	0.17	0.27	0.31	0.30	0.28	0.45	0.54	0.28	0.29	0.29	0.15	0.49	0.33	0.75	0.45	-0.17	0.14	0.19	0.75	0.61	0.98	1.40	0.66	1.20
R&D Expense	364.00K	381.00K	384.00K	444.00K	480.00K	429.00K	264.00K	301.00K	304.00K	278.00K	257.00K	407.00K	478.00K	560.00K	408.00K	326.00K	603.00K	484.00K	397.00K	620.00K	1.09M	989.00K	1.10M	-	980.00K	615.00K	658.00K	-	929.00K	467.00K	713.00K	805.00K	788.00K	760.00K	843.00K	942.00K	947.00K	768.00K	734.00K	827.00K

Profit & Loss (Annual)

Figures in USD.

Metric	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Revenue	24.06M	6.71M	722.00K	10.81M	13.38M	20.16M	21.94M	22.46M	27.17M	34.83M	38.03M	42.04M	46.09M	53.84M	66.59M
Gross Profit	10.14M	5.42M	3.72M	2.97M	3.70M	4.92M	7.19M	7.94M	9.78M	13.14M	13.57M	13.13M	12.75M	14.55M	19.51M
Operating Income	3.48M	-1.36M	-1.90M	-814.00K	-902.00K	807.00K	2.74M	2.39M	5.00M	7.07M	4.53M	5.12M	5.76M	7.17M	10.69M
Net Income	2.64M	-876.00K	-1.78M	-488.00K	-365.00K	822.00K	5.08M	1.62M	4.15M	6.11M	6.17M	4.57M	7.07M	2.13M	8.98M
Diluted EPS	0.80	-0.27	-	-	-0.09	0.20	1.25	0.37	0.97	1.50	1.57	1.21	1.95	0.60	2.67
R&D Expense	1.89M	2.07M	1.79M	1.48M	1.67M	1.20M	1.23M	1.89M	1.88M	2.31M	4.38M	2.98M	2.80M	3.19M	3.64M

Balance Sheet (Annual)

Figures in USD.

Metric	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jul 2019	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Jun 2024	Jun 2025
Total Assets	-	15.56M	12.82M	10.60M	11.71M	12.52M	11.15M	16.35M	19.92M	25.52M	-	31.13M	31.45M	39.06M	43.04M	40.32M	42.93M	43.33M	45.22M	49.09M	49.85M	51.88M	51.69M	51.82M	52.48M	61.19M
Total Equity	7.62M	10.32M	9.55M	7.94M	9.22M	8.48M	8.88M	13.71M	17.28M	17.01M	-	19.06M	-	-	-	21.13M	-	-	-	25.43M	-	-	-	31.59M	30.87M	36.63M
Cash & Equivalents	3.79M	4.69M	4.11M	1.68M	3.19M	697.00K	2.29M	4.21M	5.19M	7.74M	-	6.42M	-	-	-	3.72M	-	-	-	849.00K	-	-	-	2.94M	2.63M	419.00K
Long Term Debt	-	1.22M	393.00K	-	-	-	-	-	-	4.60M	-	3.98M	-	-	-	12.84M	-	-	-	13.59M	-	-	-	12.80M	11.96M	15.43M
Total Liabilities	-	5.24M	3.27M	2.66M	2.49M	4.04M	2.27M	2.64M	2.64M	8.51M	3.30M	12.06M	-	-	-	20.24M	-	-	-	23.66M	-	23.64M	21.79M	20.23M	21.61M	24.56M
Current Liabilities	-	4.02M	2.88M	2.31M	2.13M	3.69M	2.16M	2.58M	2.42M	4.27M	-	5.23M	-	-	-	6.27M	-	-	-	11.35M	-	-	-	9.68M	12.89M	14.63M

Cash Flows (Annual)

Figures in USD.

Metric	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Operating Cash Flow	2.90M	45.00K	-1.27M	-329.00K	-	466.00K	3.23M	3.10M	3.33M	4.95M	-	-847.00K	5.46M	6.22M	-1.68M
Investing Cash Flow	-265.00K	-259.00K	-452.00K	323.00K	-	1.59M	-1.03M	-4.12M	-1.22M	-2.29M	-	-1.24M	-885.00K	-2.23M	-238.00K
Financing Cash Flow	-1.74M	-363.00K	-709.00K	1.51M	-	-457.00K	-298.00K	2.00M	450.00K	-3.98M	-	-790.00K	-2.49M	-4.30M	-292.00K
Capital Expenditure	-	-	-	-	-	-	-	-	-1.39M	-519.00K	-	-1.67M	-974.00K	-983.00K	-1.25M
Free Cash Flow	-	-	-	-	-	-	-	-	1.94M	4.43M	-	-2.52M	4.49M	5.24M	-2.93M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-2.87M	2.09M	-305.00K	-2.21M
Share Buybacks	-	6.00K	-	-	154.00K	454.00K	312.00K	220.00K	3.98M	3.39M	5.54M	1.61M	1.55M	3.50M	3.50M

Ratios (Annual)

Figures in %.

Metric	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Gross Margin %	42.1%	80.7%	514.7%	27.4%	27.7%	24.4%	32.7%	35.4%	36.0%	37.7%	35.7%	31.2%	27.7%	27.0%	29.3%
Operating Margin %	14.5%	-20.3%	-262.5%	-7.5%	-6.7%	4.0%	12.5%	10.6%	18.4%	20.3%	11.9%	12.2%	12.5%	13.3%	16.1%
Net Margin %	11.0%	-13.1%	-247.1%	-4.5%	-2.7%	4.1%	23.2%	7.2%	15.3%	17.5%	16.2%	10.9%	15.3%	4.0%	13.5%
ROE %	25.6%	-9.2%	-22.5%	-5.3%	-4.3%	9.3%	37.1%	9.4%	24.4%	32.1%	29.2%	18.0%	22.4%	6.9%	24.5%
ROCE %	30.1%	-13.7%	-22.9%	-8.5%	-10.2%	9.0%	19.9%	13.7%	23.5%	27.3%	13.3%	13.6%	13.7%	18.1%	23.0%

Shareholding Pattern

Insiders

36.46%

Institutions

32.45%

Public Float

51.07%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	4.78%	152.51K	$9.23M
2	Vanguard Capital Management LLC	3.49%	111.33K	$6.74M
3	Punch & Associates Investment Management, Inc.	1.93%	61.73K	$3.74M
4	Dimensional Fund Advisors LP	1.78%	56.94K	$3.45M
5	Geode Capital Management, LLC	1.51%	48.35K	$2.93M
6	Northern Trust Corporation	1.46%	46.69K	$2.83M
7	State Street Corporation	1.04%	33.11K	$2.01M
8	JPMORGAN CHASE & CO	1.00%	32.04K	$1.94M
9	Quadrature Capital Ltd	0.47%	14.99K	$907.40K
10	Morgan Stanley	0.45%	14.21K	$860.60K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PDEX

Google News ue, 14 Jul 2026

Pro-Dex director (NASDAQ: PDEX) sells 998 shares in open market trade - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOanF3dGZKVy0wS1Q2OHVNMW13b3JYRDVndnJoZ1hqaUpoRE9EWTh2SmprWHJ0dXdGa2VHb2Frd0U4OE1tbkpkLVJBay1yRGNReExuaUtiZEkzZlpTMUZyd0JHSDMxN1FxSlhoZEsxN0Uxd0tuOVhmTVllaWFWeVVJRDM3NmlIT2JzcG0tV1…

Google News ue, 14 Jul 2026

Insider Sale: Director at $PDEX Sells 998 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOZmNnWUQ5REhrVjFqa0U4QTlxWlhHMHVBQTQ0VElSeDhwVG9GaXg1SWNPU0dqV3RYRkVfT1dqSmw2TkZCSGJuWHVhRzFFelpwMV8zQjBRUHZUMm1uTXRmS2VILVp3YkZTOHNUMV9ScktCT3Y4Qk9fcnkxcUxYRmQ5dTNjQk9sX0FFVzVTbV…

Google News ue, 14 Jul 2026

Pro Dex director Domingo sells $47,145 of company stock By Investing.com - Investing.com Canada

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPbFJkaHMxbGw5VWNNSkRYZ29qXzJWVFRCcVM5RjV3eTBfT3NDVXNQSldtckhqNjZDSjJqN0ZKcVZfamdYQVFxZjN1cm1tejQ3TEJBZ3hmTHdQMFRSOXUxejRoOTNfTHZMQXEtQUo2Tm9xRDlndGpKQmxDa1lHOUc2cFhSSFpXSHFtVUt6Nk…

Google News hu, 09 Jul 2026

Precision Trading with Pro-dex Inc. (PDEX) Risk Zones - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNNHFvNkFyZkZLcWZYU2xsS1M4LUpvWldsVjlFOHJRTmZvR1N2UzBiWDQ1Z1o1NXdyMFhKYVBQUzlUQzV2U0FwU05HNzF6YWhheWp2V0lWQ0VpbnJ2YjQ2ejVBVGx3c0hCcGpKRTJVcTNpcEdtNFhoQTlTUm52VXFMVWg5R3NaYXNDSjNRSE…

Google News Fri, 26 Jun 2026

Price to sales forward of Pro-Dex, Inc. – NASDAQ:PDEX - TradingView

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPQVRDaXN6ZjBzakFMbmJYUEFmUGVnRzg5cTdFcnpWSFBDRVViNnFhbXZKMHJlaHdsaVBIQURxN2IxdWRtLTg2ZlpKT1VHd01xQmV3Rk45TkVnaU8tSE12WUoxaWljYWNjNnRJM0psczA5Mm1rQk5XOHZFT1hSSU16amFjM2d6eUhUdTJZYj…

Google News Fri, 15 May 2026

Pro-Dex: Still A Buy, But Don’t Chase (NASDAQ:PDEX) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSzZHU1d6SU8zbXdiTUZsX2gxaDlIRFVZUHRqaFFlb0NKcmVDSGJBbV9LajFibWxGZzJ0Tm82ZTU3ZEFHWmtJOUEtWHFJNkhpUHJha3Q4UkFERmtYdGZheng5Mkc3MEM1S0tra1IzRG5DUGJuN3RiMGt0dlhKOEl5OWRwQTVPMUpoRmdR?o…

PDEX — Frequently Asked Questions

What is the current share price of Pro-Dex, Inc. (PDEX)?

As of 2026-07-14 21:23 PDT, Pro-Dex, Inc. (PDEX) trades at $58.26 on NasdaqCM. Its 52-week range is $23.91 to $67.50.

What is the market capitalisation of PDEX?

Pro-Dex, Inc. (PDEX) has a market capitalisation of $186.01M on NasdaqCM.

What is the P/E ratio of PDEX?

PDEX trades at a trailing price-to-earnings (P/E) ratio of 16.05. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 4.40.

What is the return on equity (ROE) of PDEX?

PDEX has a return on equity (ROE) of 29.83%. Its return on capital employed (ROCE) is 22.96%.

Is PDEX a good stock to buy?

This page provides a data-driven analysis of Pro-Dex, Inc. (PDEX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Pro-Dex, Inc. PDEX R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Pro-Dex director (NASDAQ: PDEX) sells 998 shares in open market trade - Stock Titan

Insider Sale: Director at $PDEX Sells 998 Shares - Quiver Quantitative

Pro Dex director Domingo sells $47,145 of company stock By Investing.com - Investing.com Canada

Precision Trading with Pro-dex Inc. (PDEX) Risk Zones - Stock Traders Daily

Price to sales forward of Pro-Dex, Inc. – NASDAQ:PDEX - TradingView

Pro-Dex: Still A Buy, But Don’t Chase (NASDAQ:PDEX) - Seeking Alpha

PDEX — Frequently Asked Questions

What is the current share price of Pro-Dex, Inc. (PDEX)?

What is the market capitalisation of PDEX?

What is the P/E ratio of PDEX?

What is the return on equity (ROE) of PDEX?

Is PDEX a good stock to buy?

Explore More